A landmark response analysis to determine cost-effectiveness of third-line nivolumab for small cell lung cancer

Smare, C, Dave, K, Juarez-Garcia, A, Schoenherr, N, Abraham, P, Penrod, JR, Camidge, DR, Yuan, Y

November 2019

Abstract

EU ISPOR

A partitioned survival model to determine cost-effectiveness of third-line nivolumab monotherapy for small cell lung cancer

Smare, C, Dave, K, Juarez-Garcia, A, Schoenherr, N, Abraham, P, Penrod, JR, Camidge, DR, Yuan, Y

November 2019

Abstract

EU ISPOR

November 2019

Abstract

EU ISPOR

October 2019

Abstract

AMCP Nexus

October 2019

Abstract

AMCP Nexus

October 2019

Abstract

Asian Conference on Pharmacoepidemiology

Comparative-effectiveness of pembrolizumab vs nivolumab for patients with metastatic melanoma

Moser, JC, Wei, G, Colonna, SV, Grossman, KF, Patel, SB, Hyngstrom, JR

October 2019

Abstract

ESMO Annual Congress

October 2019

Abstract

ESMO Annual Congress

Brain metastases, treatment patterns, and outcomes in ROS1-positive NSCLC patients from US oncology community centers

Krebs, MG, Perez, L, Surinach, A, Doebele, RC, Martina, R, Martinec, M, Riehl, T, Meropol, NJ, Wong, WB, Crane, G

October 2019

Abstract

ESMO Annual Congress

Flatiron-authored

Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)

Cohen, AB, Neri, B, Adamson, BJS, Scanlon, CM, Gross, CP, Meropol, NJ, Miksad, RA

October 2019

Abstract

ESMO Annual Congress

Flatiron-authored

September 2019

Abstract

ESMO Annual Congress

September 2019

Abstract

ESMO Annual Congress

September 2019

Abstract

ESMO Annual Congress

Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients

Jiao, X, Lokker, A, Snider, J, Castellanos, EH, Nanda, S, Fisher, V, Zong, J, Keating, K, Fellous, M

September 2019

Abstract

ESMO Annual Congress

Flatiron-authored

September 2019

Abstract

ESMO Annual Congress

Flatiron-authored

Prevalence and prognostic effect of high tumor mutation burden (TMB-H) across multiple less common solid cancers using a real-world dataset

Backenroth D, Shao C, Li G, Huang L,Pruitt SK, Castellanos EH, Frampton GM, Carson KR, Snow T, Singal G, Fabrizio D, Alexander BM, Jin FJ, Zhou W

September 2019

Abstract

ESMO Annual Congress

Flatiron-authored

September 2019

Abstract

ESMO Annual Congress

Flatiron-authored

Real-world evidence of male breast cancer (BC) patients treated with palbociclib (PAL) in combination with endocrine therapy (ET)

Bartlett, CH, Mardekian, J, Yu-Kite, M, Cotter, MJ, Kim, S, Decembrino, J, Snow, T, Carson, KR, Rockland, JM, Kraus, AL, Wilner, KD, Oharu, N, Schnell, P, Lu, D, Tursi, J

September 2019

Abstract

Annual Metastatic Breast Cancer Conference

Flatiron-authored

LKB1 mutations in metastatic non-small cell lung cancer (mNSCLC): Prognostic value in the real world

Golozar, A, Collins, J, Fraeman, K, Nordstrom, BL, McEwen, R, Shire, N, Higgs, B

September 2019

Abstract

World Conference on Lung Cancer

Real-world treatment patterns and survival in non-small cell lung cancer patients with EGFR exon 20 insertion mutations

Dersarkissian, M, Bhak, R, Lin, HM, Li, S, Cheng, M, Lax, A, Huang, H, Duh, MS, Ou, S-H

September 2019

Abstract

World Conference on Lung Cancer

September 2019

Abstract

World Conference on Lung Cancer

September 2019

Abstract

World Conference on Lung Cancer

September 2019

Abstract

World Conference on Lung Cancer

September 2019

Abstract

World Conference on Lung Cancer

New treatment option for ES-SCLC: Patient characteristics and use of an atezolizumab regimen in the real-world setting

McCune, S, Ton, TGN, Whipple, S, Induru, RR, Horn, L, Percent, IJ, Mekhail, T, Goldschmidt, Jr., J, Leal, TA, MacVicar, GR, Braiteh, F, Daniel, DB, Hussein, M, Mansfield, AS, Lam, S, Johnson, A, Morris, S, Spira, A

September 2019

Abstract

World Conference on Lung Cancer

September 2019

Abstract

World Conference on Lung Cancer

September 2019

Abstract

World Conference on Lung Cancer

September 2019

Abstract

World Conference on Lung Cancer

BRAF mutations are associated with increased benefit from PD-1/PD-L1 blockade compared with other oncogenic drivers in non-small cell lung cancer

Heymach, JV, Shames, DS, Albacker, LA, Frampton, GM, Alexander, BM, Miller, VA, Glisson, BS, Gibbons, DL, Papadimitrakopoulou, V, Tsao, AS, Lee, J, Swisher, S, Roth, JA, Simon, GS, Rinsurongkawong, W, Barreto, D, Zhang, J, Wu, C-J, Goldberg, ME, Le, X, Elamin, Y, Hu, S, Shen, V, Bara, I, Schulze, K, Montesion, M, Skoulidis, F, Negrão, M

September 2019

Abstract

World Conference on Lung Cancer

Real-world outcomes of advanced NSCLC patients with common and uncommon/complex EGFR mutation profiles

Riely, GJ, Lovly, CM, Messina, CGM, Bienert, S, Alexander, K, Pao, W, Magee, K, Baxi, SS, Doebele, RC

September 2019

Abstract

World Conference on Lung Cancer

Flatiron-authored

September 2019

Abstract

World Conference on Lung Cancer

Flatiron-authored

Real-world characterization of advanced non-small cell lung cancer in never smokers

Kerrigan, KC, Halland, B, Adamson, BJS, Patel, SB, Akerley, WL

September 2019

Abstract

World Conference on Lung Cancer

Flatiron-authored

Retrospective analysis of real-world clinico-genomic data for clinical impact of genomic profiling of CTDNA in NSCLC

Madison, R, Schrock, AB, Gregg, JP, Carson, KR, Castellanos, EH, Singal, G, Miller, VA, Ali, SM, Alexander, BM, Chung, JH

September 2019

Abstract

World Conference on Lung Cancer

Flatiron-authored

Comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive (ROS1+) NSCLC patients

Doebele, RC, Perez, L, Trinh, H, Martinec, M, Martina, R, Riehl, T, Krebs, MG, Meropol, NJ, Wong, WB, Crane, G

September 2019

Abstract

World Conference on Lung Cancer

Flatiron-authored

Development of a time to treatment metric across an NCI designated academic health system

Najarian, ML, Shaw, P, Severino, KM, Hamrick, HJ, Adelson, KB, Miksad, RA

September 2019

Abstract

ASCO Quality Care Symposium

Flatiron-authored

August 2019

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

August 2019

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

August 2019

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

August 2019

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Flatiron-authored

July 2019

Abstract

Joint Statistical Meeting

Flatiron-authored

June 2019

Abstract

International Conference on Malignant Lymphoma

Building control arms for cancer clinical trials from real-world data

Bennette, CS, Segal, BD, Miksad, RA, Bellomo, L, Nussbaum, NC, Sarkar, S, Tucker, MG, Abernethy, AP

June 2019

Abstract

HTAi

Flatiron-authored

June 2019

Abstract

Congress of the European Hematology Association

Patient characteristics, treatments, and transplant frequency in newly-diagnosed (NDMM) multiple myeloma

Karve, S, Downer, MK, Kamalakar, R, Maher, J, Pauff, J, Maciag, P, Gasparetto, C

June 2019

Abstract

Congress of the European Hematology Association

Affordable Care Act Medicaid expansion impact on racial disparities in time to cancer treatment

Adamson B, Cohen AB, Estevez M, Magee K, Williams E, Gross CP, Meropol NJ, Davidoff AJ

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Organ dysfunction and clinical outcomes in patients treated with immune checkpoint inhibitors

Liu Q, Sharon E, Zineh I, Xie D, Baxi SS, Liu C, Zhi J, Torres AZ, Gossai A, Sridhara R, Booth B, Blumenthal GM, Huang S-M, Khozin S

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Tumor mutational burden and PD-L1 expression as predictors of response to immunotherapy in NSCLC

Castellanos E, Snider J, Ali SM, Backenroth D, Albacker LA, Murugesan K, Li G, Frampton GM, Alexander BM, Carson KR

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Impact of Oncology Care Model reporting requirements on quality of care

Castellanos E, Orlando A, Hamrick J, Ma X, O'Connell G, Meropol NJ, Adamson B.

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Real-world evidence of male breast cancer patients treated with palbociclib in combination with endocrine therapy

Bartlett CH, Mardekian J, Yu-Kite M, Cotter MJ, Kim S, Decembrino J, Snow T, Carson KR, Rockland JM, Kraus AL, Wilner KD, Oharu N, Schnell P, Lu D, Tursi J

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2019

Abstract

ASCO Annual Meeting

Genomic characterization of lung tumors and metastatic sites in advanced NSCLC

Willard MD, Smyth EN, Tiu RV, Beyrer J, Zhu YE, Bowman L, Sheffield KM, Han Y, Brastianos P

June 2019

Abstract

ASCO Annual Meeting

Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents

Giri S, Huntington SF, Wang R, Zeidan AM, Podoltsev NA, Gore S, Ma X, Gross CP, Davidoff AJ, Neparidze N

June 2019

Abstract

ASCO Annual Meeting

Utilization and reach of the Fight Colorectal Cancer Late Stage MSS CRC Clinical Trial Finder

Garcia R, Dwyer A, Worrall S, Heery CR, Deming DA, Benson AB, Davis A.

June 2019

Abstract

ASCO Annual Meeting

A real-world evidence study of CDK4/6 inhibitor treatment patterns and outcomes in metastatic breast cancer by gBRCA mutation status

McLaurin K, Dalvi T, Collins JM, Nordstrom BL, McCutcheon S, Bennett JC, Murphy BR, Singhal PK, Briceno JM

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

Overall survival with oral selinexor plus low dose dexamethasone in patients with triple class refractory-multiple myeloma

Richardson PG, Jagannath S, Chari A, Vogl DT, Dimopoulos MA, Moreau P, Dingli D, Wei LJ, Li L, Tang S, Reichman W, Kauffman MG, Shah JJ, Shacham S, Lonial S.

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

Real-world clinical burden of aggressive disease in advanced/metastatic non small cell lung cancer

Batus M, Stefaniak VJ, Molife C, Clarke JM, Winfree KB, Mitchell L, Cui ZL, Bonom PD

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

Carboplatin-based chemotherapy versus immunotherapy in metastatic urothelial carcinoma

Feld E, Harton J, Meropol NJ, Adamson B, Parikh RB, Galsky MD, Cohen AB, Narayan V, Christodouleas JP, Vaughn DJ, Hubbard RA, Mamtani R

June 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

Clinical characteristics, treatment patterns, and overall survival in advanced NSCLC patients with and without brain metastases

Smyth EN, Tiu RV, Willard MD, Beyrer J, Zhu YE, Bowman L, Sheffield KM, Han Y, Brastianos P

June 2019

Abstract

ASCO Annual Meeting

June 2019

Abstract

ASCO Annual Meeting

Comparative efficacy analysis between entrectinib trial and crizotinib real-world ROS1 fusion-positive (ROS1+) NSCLC patients

Doebele, RC, Perez, L, Trinh, H, Martinec, M, Martina, R, Riehl, T, Krebs, MG, Meropol, NJ, Wong, WB, Crane, G

May 2019

Abstract

ASCO Annual Meeting

Flatiron-authored

May 2019

Abstract

ISPOR Annual Meeting

May 2019

Abstract

ISPOR Annual Meeting

May 2019

Abstract

ISPOR Annual Meeting

May 2019

Abstract

ISPOR Annual Meeting

May 2019

Abstract

ISPOR Annual Meeting

Flatiron-authored

May 2019

Abstract

ISPOR Annual Meeting

Flatiron-authored

Machine Learning Model for Cancer Biomarker Identification in Electronic Health Records

Ambwani G, Cohen A, Estévez M, Singh N, Adamson B, Nussbaum N, Birnbaum B

May 2019

Abstract

ISPOR Annual Meeting

Flatiron-authored

May 2019

Abstract

ISPOR Annual Meeting

Flatiron-authored

April 2019

Abstract

European Lung Cancer Conference

April 2019

Abstract

European Lung Cancer Conference

Treatment characteristics of patients with locally advanced or metastatic non-small cell lung cancer receiving atezolizumab monotherapy in US clinical practice

Frueh M, Rahma OE, Pachynski RK, Mazieres J, Goldschmidt, Jr J, Ton TGN, Mhatre SK, Chuo C-Y, Martinalbo J, Davies J, Juergens R.

April 2019

Abstract

European Lung Cancer Conference

April 2019

Abstract

AACR Annual Meeting

Flatiron-authored

April 2019

Abstract

AACR Annual Meeting

March 2019

Abstract

NCCN Annual Conference

Flatiron-authored

Real-world trends in first-line checkpoint inhibitor use in advanced urothelial cell carcinoma

Parikh RB, Galsky MD, Baxi SS, Adamson B, Cohen AB, Feld E, Christodouleas JP, Boursi SB, Meropol NJ, Mamtani R

February 2019

Abstract

ASCO GU Symposium

Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma at the end of life: Insights from real-world practice

Parikh RB, Galsky MD, Gyawali B, Riaz F, Kaufmann TL, Cohen AB, Adamson B, Gross CP, Meropol NJ, Mamtani R

February 2019

Abstract

ASCO GU Symposium

February 2019

Abstract

ASCO GU Symposium

February 2019

Abstract

ASCO GU Symposium

February 2019

Abstract

ASCO GU Symposium

February 2019

Abstract

ASCO GU Symposium

January 2019

Abstract

ASCO GI Symposium

January 2019

Abstract

ASCO GI Symposium

January 2019

Abstract

ASCO GI Symposium

December 2018

Abstract

ESMO Immuno-Oncology Congress

December 2018

Abstract

Machine Learning for Health (ML4H) Workshop

Flatiron-authored

Influence of Prognostic Factors on Outcomes Among Metastatic Breast Cancer Patients Treated with CDK4&6 Inhibitors in Routine Clinical Practice

Saverno KR, Carter GC, Li L, Battiato LA, Huang Y-J, Smyth EN, Price GL, Sheffield KM, Baxi SS, Kuk D, Seidman AD

December 2018

Abstract

San Antonio Breast Cancer Symposium

Flatiron-authored

December 2018

Abstract

San Antonio Breast Cancer Symposium

A real world evidence study of BRCA mutations and survival in HER2-negative breast cancer

Dalvi T, McLaurin K, Briceno J, Nordstrom B, Bennett J, Hettle R, Murphy B, Collins J, McCutcheon S

December 2018

Abstract

San Antonio Breast Cancer Symposium

December 2018

Abstract

San Antonio Breast Cancer Symposium

Real-world survival of heavily pretreated patients with refractory HR+, HER2- metastatic breast cancer receiving single-agent chemotherapy – A comparison with MONARCH 1

Rugo H, Dieras V, Cortes J, Patt D, Wildiers H, O'Shaughnessy J, Zamora E, Yardley DY, Carter GC, Sheffield KM, Li L, Andre VA, Derbyshire RE, Li XI, Frenzel M, Huang Y-J, Dickler MN, Tolaney SM

December 2018

Abstract

San Antonio Breast Cancer Symposium

December 2018

Abstract

Blood Journal

Flatiron-authored

December 2018

Abstract

Blood Journal

Flatiron-authored

December 2018

Abstract

Blood Journal

Flatiron-authored

December 2018

Abstract

American Society of Hematology Annual Meeting

December 2018

Abstract

Blood Journal

Treatment Patterns Among Adults with Newly Diagnosed Primary Immune Thrombocytopenia in the United States

Cetin K, McGrath L, Overman R, Reams D, Sharma A, Brookhart MA, Altomare I, Wasser JS

December 2018

Abstract

Blood Journal

December 2018

Abstract

Blood Journal

December 2018

Abstract

Blood Journal

Comparative Efficacy Of Nivolumab±ipilimumab Versus Standard of Care (SOC) For Third-Line (3L) Patients with Recurrent Small Cell Lung Cancer (SCLC) Using Population-Adjusted Indirect Comparison

Cope S, Popoff E, Keeping S, Goldgrub R, Jansen JP, Penrod J, Abraham P, Camidge DR, Korytowsky B, Gu T, Schoenherr N, Juarez-Garcia A, Le T, Yuan Y

November 2018

Abstract

EU ISPOR

November 2018

Abstract

Congress of the European Association of Dermato Oncology

November 2018

Abstract

Congress of the European Association of Dermato Oncology

Flatiron-authored

October 2018

Abstract

Society of Melanoma Research

October 2018

Abstract

Society of Melanoma Research

October 2018

Abstract

Society of Melanoma Research

October 2018

Abstract

ESMO Annual Congress

October 2018

Abstract

ESMO Annual Congress

Flatiron-authored

October 2018

Abstract

ESMO Annual Congress

October 2018

Abstract

ESMO Annual Congress

October 2018

Abstract

ESMO Annual Congress

October 2018

Abstract

ESMO Annual Congress

October 2018

Abstract

ESMO Annual Congress

October 2018

Abstract

ESMO Annual Congress

October 2018

Abstract

ESMO Annual Congress

October 2018

Abstract

ESMO Annual Congress

October 2018

Abstract

ESMO Annual Congress

Prognostic value of patient-reported outcomes (PROs) in advanced cancer

Patel, SB, Akerley, WL, Ose, D, Haydell, T, Martineau, J, Dunson, Jr, WA, Chalmers, AW, Cannon, L, Meropol, NJ, Halland, B

September 2018

Abstract

ASCO Quality Care Symposium

Flatiron-authored

September 2018

Abstract

ASCO Quality Care Symposium

Development of a dashboard for end-of-life care at an academic hospital

Adelson, KB, Meropol, NJ, Hamrick, HJ, Haydell, T, Martineau, J, Kraut, J, Severino, KM, Lilenbaum, R

September 2018

Abstract

ASCO Quality Care Symposium

Flatiron-authored

Real-time assessment of resource utilization and subsequent cost analysis in cancer patients (pts) near the end of life (EOL)

McPherson, JP, Patel, SB, Igumnova, E, Pettit, J, Ose, D, Haydell, T, Martineau, J, Meropol, NJ, Beck, AC

September 2018

Abstract

ASCO Quality Care Symposium

Flatiron-authored

Distinctive Clinical Characteristics of SCLC in Never-Smokers

Mian I, Nichols S, Abernethy AP, Carson K, Maignan K, Torres AZ, Snider J, Frampton G, Li G, Sharon E, Szabo E, Thomas A

September 2018

Abstract

World Conference on Lung Cancer

Flatiron-authored

Sequencing of Ramucirumab+Docetaxel Postimmune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer

Clarke JM, Stefaniak VJ, Batus M, Winfree KB, Molife C, Cui Z, Han Y, Tawney MK, Bonomi PD

September 2018

Abstract

World Conference on Lung Cancer

Prognosis of Non-Driver, Never Smoker Metastatic Non-Small Lung Cancer (NSCLC)

Chalmers AW, Haaland B, Patel SB, Moynahan K, Cannon L, Akerley W

September 2018

Abstract

World Conference on Lung Cancer

Ramucirumab+Docetaxel Usage Following Rapid Disease Progression in Real World Advanced Non-Small Cell Lung Cancer Patients

Batus M, Molife C, Clarke JM, Stefaniak VJ, Winfree KB, Cui Z, Han Y, Tawney MK, Bonomi PD

September 2018

Abstract

World Conference on Lung Cancer

September 2018

Abstract

World Conference on Lung Cancer

Treatment Patterns and Overall Survival Following Biomarker Testing in Real-World Advanced NSCLC Patients

Barlesi F, Paz-Ares L, Page D, Shewade A, Lambert P, Mughal T, Gay L, Khorshid M, Arnieri B, Capra W, Foser S, Mascaux C, Bubendorf L, Wang L

September 2018

Abstract

World Conference on Lung Cancer

Real World Biomarker Testing and Treatment Patterns in Patients with Advanced NSCLC Receiving EGFR TKIs

Chiang A, Fernandes A, Pavilack M, Wu J, Laliberté F, Duh MS, Chehab N, Subramanian J

September 2018

Abstract

World Conference on Lung Cancer

September 2018

Abstract

Biennial Meeting of the International Gynecologic Cancer Society

August 2018

Abstract

ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics

The Impact of Missing Deaths on Survival Analyses Conducted in an Oncology EHR Database

Carrigan G, Whipple S, Taylor M, Torres AZ, Gossai A, Arnieri B, Tucker M, Hofmeister PP, Lambert P, Griffith S, Capra W

August 2018

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Flatiron-authored

Proof-of-Concept for using External Control Arms Derived from Electronic Health Records (EHR) to Replace Control Arms from Randomized Controlled Trials (RCT)

Carrigan G, Whipple S, Capra W, Taylor M, Lu M, Arnieri B, Brown JS, Abernethy AP, Copping R, Rothman KJ

August 2018

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Flatiron-authored

August 2018

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

August 2018

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

August 2018

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Development and Validation of a High-Quality Composite Real-World Mortality Endpoint

Curtis MD, Griffith S, Tucker M, Taylor M, Capra W, Carrigan G, Holzman B, Torres AZ, You P, Arnieri B, Abernethy AP

June 2018

Abstract

Academy Health Annual Research Meeting

Flatiron-authored

Prognostic value of patient-reported outcomes (PROs) in advanced cancer

Patel, SB, Akerley, WL, Ose, D, Haydell, T, Martineau, J, Dunson, Jr., WA, Chalmers, AW, Cannon, L, Meropol, NJ, Halland, B

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2018

Abstract

ASCO Annual Meeting

June 2018

Abstract

ASCO Annual Meeting

Real-world Data (RWD) on Tumor Response (rwTR) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients Receiving Cancer Immunotherapy and Targeted Therapies

Lu M, Sadetsky N, Lambert P, Whipple S, Taylor M, Riehl T, Riely GJ

June 2018

Abstract

ASCO Annual Meeting

Risk Stratification Using Patient-Reported Outcomes (PROs) in Patients (pts) with Advanced Cancer

Patel SB, Haaland B, Ose D, Haydell T, Martineau J, Dunson W, Chalmers AW, Cannon L, Kissell B, Meropol N, Akerley W

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

Development of a Dashboard for End-of-Life Care at an Academic Hospital

Adelson K, Meropol N, Hamrick HJ, Haydell T, Martineau J, Kraut J, Severino KM, Lilenbaum R

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

Age-Related Real-World Outcomes for Patients (pts) with Metastatic Colorectal Cancer (mCRC)

Curtis MD, Nussbaum N, Hamrick HJ, Bennette CS, Meropol N, Miksad RA

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2018

Abstract

ASCO Annual Meeting

June 2018

Abstract

ASCO Annual Meeting

June 2018

Abstract

ASCO Annual Meeting

June 2018

Abstract

ASCO Annual Meeting

June 2018

Abstract

ASCO Annual Meeting

June 2018

Abstract

ASCO Annual Meeting

June 2018

Abstract

ASCO Annual Meeting

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

Real World Outcomes of Metastatic Pancreatic Cancer (mPC) Patients (pts) Treated with Liposomal Irinotecan (nal-IRI) in the US

Barzi A, Miksad RA, Surinach A, Corvino F, Wang S, Torres AZ, Mamlouk KK, Pulgar SJ, Bekaii-Saab TS

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

Sequencing of Ramucirumab (ram) and Immune Checkpoint Inhibitors (ICIs) in Platinum (Pt)-Treated Real-World Patients (pts) with Advanced Non-Small Cell Lung Cancer (aNSCLC)

Clarke JM, Molife C, Miksad RA, Batus M, Winfree KB, Gossai A, Stefaniak VJ, Foster R, Cui Z, Torres AZ, Feuchtbaum D, Tawney MK, Bonomi PD

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

Identifying the Prognostic Significance of Genomic Alterations in a Real-World, EHR-Derived Clinico-Genomic Database (CGDB)

Agarwala V, Backenroth D, Singal G, O'Connell C, Li G, Alpha-Cobb G, Kaushik G, Carson K, Miller V, Abernethy AP

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

Prevalence of Microsatellite Instability and Association with Pembrolizumab (P) Usage in a Real-World Clinico-Genomic Database

O'Connell C, Backenroth D, Singal G, Agarwala V, Li G, Kaushik G, Alpha-Cobb G, Kao CK, Miller V, Abernethy AP, Carson K

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

ICD-Coded Information on Sites of Metastasis in Oncology Real-World Data is Specific But Not Sensitive

Parrinello CM, Seidl-Rathkopf K, Bennette CS, Bourla A, Nussbaum N, Carson K, Abernethy AP

May 2018

Abstract

ISPOR Annual Meeting

Flatiron-authored

May 2018

Abstract

ISPOR Annual Meeting

Flatiron-authored

May 2018

Abstract

Academy Health Annual Research Meeting

Flatiron-authored

Identification of Resistance Mechanisms to EGFR Treatment in the Real World Using a Clinicogenomic Database

Singal G, Agarwal A, Kaushik G, O'Connell C, Alpha-Cobb G, Caron T, Bourque D, Guria A, Frank S, Frampton G, Carson K, Abernethy AP, Miller V

April 2018

Abstract

American Association for Cancer Research Annual Meeting

Flatiron-authored

Use of Cancer Immunotherapies in the Real-World in the Setting of Microsatellite Instability

Agarwala V, Gossai A, Singal G, O'Connell C, Li G, Kao K, Bourque D, Feuchtbaum D, Nunnally A, Frampton G, Ali S, Abernethy AP, Kramarz S, Trabucco SE

January 2018

Abstract

ASCO-SITC Clinical Immuno-Oncology Symposium

Flatiron-authored

January 2018

Abstract

ASCO-SITC Clinical Immuno-Oncology Symposium

January 2018

Abstract

ASCO-SITC Clinical Immuno-Oncology Symposium

January 2018

Abstract

ASCO Gastrointestinal Cancers Symposium

January 2018

Abstract

ASCO Gastrointestinal Cancers Symposium

December 2017

Abstract

American Society of Hematology Annual Meeting

December 2017

Abstract

American Society of Hematology Annual Meeting

December 2017

Abstract

American Society of Hematology Annual Meeting

December 2017

Abstract

American Society of Hematology Annual Meeting

December 2017

Abstract

American Society of Hematology Annual Meeting

December 2017

Abstract

American Society of Hematology Oncology

December 2017

Abstract

San Antonio Breast Cancer Symposium

Treatment Patterns for Young Women with HR+/HER2- Metastatic Breast Cancer in the United States in the Era of CDK 4/6 Inhibitors

Burstein H, Mayer E, DeMichele A, Harnett J, Mardekian J, McRoy L, Huang Bartlett C, Koehler M, Fahed Rimawi M

December 2017

Abstract

San Antonio Breast Cancer Symposium

November 2017

Abstract

San Antonio Breast Cancer Symposium

Flatiron-authored

October 2017

Abstract

World Conference on Lung Cancer

Utilization and Timing of Foundation Medicine (FMI) Testing in U.S. Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients

Wang L, Page D, Shewade A, Lambert P, Arnieri B, Capra W, Khorshid M, Mughal T, Gay L, Foser S

October 2017

Abstract

World Conference on Lung Cancer

October 2017

Abstract

World Conference on Lung Cancer

October 2017

Abstract

World Conference on Lung Cancer

Real-World Management of Patients with EGFR Mutation-Positive NSCLC in the US

Li Y, Appius A, Pattipaka T, Feyereislova A, Cassidy A, Ganti A

October 2017

Abstract

World Conference on Lung Cancer

October 2017

Abstract

World Conference on Lung Cancer

Immune Checkpoint Inhibitor (ICPI) Efficacy and Resistance Detected by Comprehensive Genomic Profiling (CGP) in Non-Small Cell Lung Cancer (NSCLC)

Ross J, Goldberg M, Albacker L, Gay L, Agarwala V, Elvin J, Vergillo J, Ramkissoon S, Severson E, Daniel S, Ali S, Schrock A, Frampton G, Fabrizio D, Miller V, Singal G, Abernethy AP, Stephens P

September 2017

Abstract

ESMO Annual Congress

Flatiron-authored

Analyzing Biomarkers of Cancer Immunotherapy (CIT) Response Using a Real-World Clinico-Genomic Database

Singal G, Miller P, Agarwala V, Li G, Gossai A, Albacker L, Goldberg M, He J, Frank S, Bourque D, Ivanov V, Fabrizio D, Caron T, Parker A, Guria A, Miller V, Elvin J, Ross J, Abernethy AP, Stephens P

September 2017

Abstract

ESMO Annual Congress

Flatiron-authored

September 2017

Abstract

ESMO Annual Congress

September 2017

Abstract

ESMO Annual Congress

June 2017

Abstract

ESMO World Congress on Gastrointestinal Cancer

June 2017

Abstract

ESMO World Congress on Gastrointestinal Cancer

Adoption of Immunotherapy into Real World Practice: Insights from the Use of Checkpoint Inhibitors

O’Connor J, Seidl-Rathkopf K, You P, Nussbaum N, Torres AZ, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy AP, Gross C

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

Racial Disparities in the Use of Programmed Death-1 Checkpoint Inhibitors

O’Connor J, Seidl-Rathkopf K, You P, Nussbaum N, Torres AZ, Fessele K, Darius K, Adelson K, Yin E, Presley C, Chiang A, Ross J, Abernethy AP, Gross C

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

Disparities in Next Generation Sequencing in a Population-Based Community Cohort of Patients with Advanced Non-Small Cell Lung Cancer

Presley C, Chiang A, Longtine J, Soulos P, Adelson K, Herbst R, Nussbaum N, Sorg R, Abernethy AP

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

Development and Validation of a Real-World Clinico-Genomic Database

Singal G, Miller P, Agarwala V, He J, Gossai A, Frank S, Bourque D, Bowser B, Caron T, Baydur E, Seidl-Rathkopf K, Ivanov I, Parker A, Guria A, Frampton G, Jaskiw A, Feuchtbaum D, Nussbaum N, Abernethy AP, Miller V

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2017

Abstract

ASCO Annual Meeting

June 2017

Abstract

ASCO Annual Meeting

Characteristics of Advanced NSCLC Patients Receiving Molecular Diagnostic Testing in US Routine Clinical Practice

Wang L, Shewade A, Lambert P, Arnieri B, Capra W, Khroshid M, Mughal T, Gay L, Page D, Foser S

June 2017

Abstract

ASCO Annual Meeting

June 2017

Abstract

ASCO Annual Meeting

Real-World Treatment Pattern and Discontinuation of Systemic Combination Therapies in Metastatic Melanoma

Qiu Y, Li Z, Tang J, Atanasov P, Mahmood S, Grzegorzewski K, Chen L, Chen J

June 2017

Abstract

ASCO Annual Meeting

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

Implementation of the IOM 13 Point Care Plan by OCM Practices

Fargnoli B, Jaffe N, Bauer-Levey N, Cowing K, Schneider J, Parulkar R, Lee D, Harary O, Holleran R, Zhang S, Revol C, Tran D, Shah R, Abernethy AP, Kolodziej M

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

Electronic Calculation of Quality Measures in the EMR is Highly Dependent on Data Capture in Structured Fields: The Oncology Care Model (OCM) Quality Reporting Experience

Hamrick HJ, Revol C, Parulkar R, Lemmers O, Gippetti J, Bauer-Levey N, Lee D, Fugaro A, Kolodziej M, Green R, Abernethy AP

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

May 2017

Abstract

European Lung Cancer Conference

Real-World Rates of Chemotherapy Use Near the End of Life (EOL) in Cancer Patients

Agarwala V, Kraut J, Gippetti J, Revol C, Peterson D, Fessele K, Abernethy AP

March 2017

Abstract

NCCN Annual Conference

Flatiron-authored

The NCCN-Flatiron Outcomes Database: Collaborative Evidence Development and Quality Improvement in Oncology

Agarwala V, Birnbaum B, Gippetti J, Talcott L, Kraut J, Bowser B, Delgado J, Nightingale C, Lvov M, Nussbaum N, Connolly D, Martineau J, Darius K, Fessele K, McClure J, Fitzgerald L, Carlson R, Abernethy AP

March 2017

Abstract

NCCN Annual Conference

Flatiron-authored

Total Cost of Care in Patients with Advanced Non-Small Cell Lung Cancer Receiving Oral Targeted Therapy vs. Standard Therapy

Gabriel PE, Berman AT, Guttman D, Stetson R, Kruse G, Morrissette J, Agarwala V, Kraut J, Abernethy AP, Shulman LN, Evans T

March 2017

Abstract

Personalized Medicine Conference-Fusion

Flatiron-authored

Chemotherapy Use Near End of Life (EOL): Measuring Real World Benchmarks

Kraut J, Gippetti J, Peterson D, Agarwala V, Revol C, Fessele K, Abernethy AP

March 2017

Abstract

ASCO Quality Care Symposium

Flatiron-authored

March 2017

Abstract

ASCO Quality Care Symposium

Flatiron-authored

March 2017

Abstract

ASCO Quality Care Symposium

Validation of Diagnosis Codes to Identify Side of Colon in an Electronic Health Record Registry

Luhn P, Kuk D, Carrigan G, Nussbaum N, Sorg R, Rohrer R, Tucker M, Arnieri B, Taylor M, Abernethy AP

January 2017

Abstract

ASCO Gastrointestinal Cancers Symposium

Flatiron-authored

January 2017

Abstract

ASCO Gastrointestinal Cancers Symposium

December 2016

Abstract

European Society for Medical Oncology ASIA

December 2016

Abstract

American Society of Hematology Annual Meeting

December 2016

Abstract

American Society of Hematology Oncology

October 2016

Abstract

EU ISPOR

Initiation and Adherence with Bone-Targeting Agents in US Men with Bone Metastases from Prostate Cancer

Butler A, Ceitin K, Hernandez RK, Overman R, Kim J, Reams D, Hirsch B, Abernethy AP, Liede A, Brookhart A

August 2016

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Flatiron-authored

Concomitant use of emerging therapies and bone-targeting agents in prostate cancer: Observations from real-world data

Finelli, A, Hernandez, RK, Lethen, J, Wade, SW, Warner, D, Abernethy, AP, Liede, A

June 2016

Abstract

Meeting of the Canadian Urological Association

Flatiron-authored

Initiation and Adherence with Bone-Targeting Agents in US Men with Bone Metastases from Prostate Cancer

Butler A, Ceitin K, Hernandez RK, Overman R, Kim J, Reams D, Hirsch B, Abernethy AP, Liede A, Brookhart A

June 2016

Abstract

Meeting of the Canadian Urological Association

Flatiron-authored

June 2016

Abstract

ASCO Annual Meeting

Flatiron-authored

Initiation and Adherence with Bone-Targeting Agents in US Men with Bone Metastases from Prostate Cancer

Butler A, Ceitin K, Hernandez RK, Overman R, Kim J, Reams D, Hirsch B, Abernethy AP, Liede A, Brookhart A

June 2016

Abstract

ASCO Annual Meeting

Flatiron-authored

Contemporary management of advanced non-small cell lung cancer (aNSCLC) in a large, real-world cohort

Presley, CJ, Harrington, E, Gippetti, J, Agarwala, V, Bowser, B, Adelson, KB, Herbst, RS, Abernethy, AP, Gross, CP

June 2016

Abstract

ASCO Annual Meeting

Flatiron-authored

January 2016

Abstract

ASCO Gastrointestinal Cancers Symposium

January 2016

Abstract

ASCO Gastrointestinal Cancers Symposium

September 2015

Abstract

European Cancer Congress

Flatiron-authored

Real-World Bortezomib Usage Patterns Among Patients with Relapsed/Refractory Multiple Myeloma

Calkins G, Kohansimeh J, Krishna A, Green R, Curtis MD, Lindberg F, Jaskiw A, Larrabee K, Terry M, Feinstein RN, Plotkin L, Palladino ML, Nicacio L

June 2015

Abstract

EHA Learning Center

Flatiron-authored

BRAF, KIT, and NRAS Testing Patterns and Results in Metastatic Melanoma

Abernethy AP, Fung C, Richardson P, Eisenberg D, Connolly D, Terry M, Feinstein RN, Tucker M, Miller C, Nicacio L

June 2015

Abstract

ASCO Annual Meeting

Flatiron-authored

May 2015

Abstract

ASCO Annual Meeting

Flatiron-authored